Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas by Bignotti, E et al.
Trefoil factor 3: a novel serum marker identified by gene












1 and AD Santin*,1,4
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy;
2Section of
Medical Statistics and Biometry, Department of Biomedical Sciences and Biotechnology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy;
3Department of Pathology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy;
4Department of Obstetrics, Gynecology and Reproductive
Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA
This study identifies the genetic fingerprint of poorly differentiated endometrioid endometrial carcinomas (G3-EEC) and analyses the
potential utility of trefoil factor 3 (TFF3) as novel serum marker in G3-EEC. Affymetrix microarrays were used to identify the gene
expression patterns of 19 snap-frozen G3-EEC and 15 normal endometrium (NE) biopsies. Quantitative real-time PCR (qRT-PCR)
and immunohistochemistry were used to validate TFF3 expression. Finally, TFF3 serum levels were determined by ELISA in 25
G3-EEC patients, 42 healthy controls, and in 13 endometrial hyperplasia patients. Hierarchical cluster analysis showed TFF3 as the top
differentially expressed gene between 363 upregulated genes in G3-EEC, when compared with NE. Trefoil factor 3 gene expression
levels analysed by qRT-PCR significantly correlated with Affymetrix results (Po0.001; rs¼0.85). By immunohistochemistry, TFF3
protein was significatively more expressed in EEC compared with NE (Po0.01), with cytoplasmatic positivity in 79% G3-EEC and
18% NE. Patients harbouring G3-EECs had significantly higher TFF3 serum concentration by ELISA when compared with healthy
patients (Po0.001) or patients harbouring endometrial hyperplasia (P¼0.012). In conclusion, TFF3 is highly expressed at gene and
protein level in G3-EEC. Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for
early detection and/or monitoring of G3-EEC patients.
British Journal of Cancer (2008) 99, 768–773. doi:10.1038/sj.bjc.6604546 www.bjcancer.com
Published online 5 August 2008
& 2008 Cancer Research UK
Keywords: G3 endometrioid endometrial carcinoma; microarray technology; trefoil factor; serum marker; sandwich ELISA
                                                     
Endometrial carcinoma (EC) is the most common gynecologic
malignancy in Western world and it is characterized by two
clinical/pathogenic types (Bokhman, 1983). Type I ECs, which
account for the majority of cases, are oestrogen-related tumours
usually well differentiated and endometrioid in histology. Typically
these patients have a favourable prognosis with appropriate
therapy. In contrast, Type II ECs include poorly differentiated
endometrioid endometrial tumours (G3-EEC), serous papillary,
and clear cell ECs. These tumours are not associated with
hyperoestrogenic factors, and they are more likely to be deeply
invasive in the myometrium and/or metastatic at presentation and
often recur despite aggressive clinical interventions. Poorly
differentiated endometrioid endometrial carcinomas account for
the majority of Type II Ecs, and unfortunately, to date, no good
marker for screening or disease monitoring for these biologically
aggressive cancers is available. In this regard, CA125 is often used
in clinical practise to monitor EC patients (Duk et al, 1986).
However, this marker appears to have limited utility in monitoring
the effects of adjuvant therapy or in the prediction of tumour
recurrence (Chung et al, 2006).
Large-scale gene expression analysis using microarrays repre-
sents a powerful tool to discover gene expression patterns
characteristic for different human tumours. Consistent with this
view, in the last few years, several investigators have used this
technology in an attempt to identify gene expression profiling
characteristic of ECs and its different histological subtypes (Risinger
et al, 2003; Planaguma ` et al, 2004). However, although the degree of
histologic differentiation in EEC patients has long being accepted as
the most sensitive indicator of prognosis, to our knowledge, no
studies have investigated the genetic fingerprint of G3-EEC
separately from those of G1 and G2-EEC and/or the other histologic
variants of Type II EC (i.e., serous papillary and clear cell tumours).
In this study, we have carefully analysed the gene expression
pattern of 19 G3-EECs and 15 normal endometria (NEs) using
oligonucleotide microarrays with probe sets complementary to
38500 well-characterized human genes. Among the 363 genes
upregulated in EECs when compared with NEs, human intestinal
trefoil factor 3 (TFF3, gene symbol hITF) was found as the top
highly expressed gene in G3-EECs. In this regard, TFF3 belongs to
a family of small mucin-associated polypeptides, mainly present
in the gastrointestinal tract and other epithelial tissues, known to
play an important function in maintaining mucosal integrity
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s(Hoffmann et al, 2001). Recently, TFFs have been reported to be
overexpressed at the gene and protein level in human neoplasms,
including intestinal, pancreatic, and prostate cancers (Taupin et al,
1996; Terris et al, 2002; Garraway et al, 2004).
In this study, with the aim to investigate the potential utility of
TFF3 in the diagnosis and/or monitoring of G3-EEC, we have
validated its expression levels by quantitative real-time PCR,
whereas protein expression was tested by immunohistochemistry.
Furthermore, using a novel in-house made ELISA assay, we have
measured preoperative TFF3 serum levels in patients with
G3-EECs, with endometrial hyperplasia, and in healthy
female controls. In addition, we have compared TFF3 serum levels




A total of 19 snap-frozen G3-EECs and 15 NE were collected from
the Division of Gynecologic Oncology at the University of Brescia
(Italy) from 2003 to 2006. Study approval was obtained from the
Institutional Review Board, and all patients signed an informed
consent according to institutional guidelines. Tumour tissues were
obtained from women undergoing complete surgical staging,
which included total abdominal hysterectomy, bilateral salpingo-
oophorectomy, pelvic and periaortic lymphadenectomy, and
peritoneal washings for cytology. All patients were staged in
accordance with International Federation of Gynaecologists and
Obstetricians (FIGO) guidelines. None of the patients had received
preoperative chemotherapy or radiation. Moreover, samples of NE
were collected from age-matched patients.
Tumour and normal tissues sharp-dissection, liquid nitrogen
freezing, and epithelial purity checking were performed as
previously reported (Bignotti et al, 2006).
Immunohistochemical analysis was performed on 38 G3-EECs
and 22 NEs, collected in the Department of Pathology, University
of Brescia, Italy.
Preoperative serum samples from 25 patients with G3-EEC, 13
patients with endometrial hyperplasia (EH), and 42 healthy female
controls were stored. All serum samples were collected before any
patient treatment, frozen in liquid nitrogen within 2h of blood
drawing, and stored at  801C.
Total RNA extraction and Genechip hybridisation
Total RNA extraction, quantification, and quality assessment were
performed as previously described (Bignotti et al, 2006). Labelling
of samples and hybridisation to the Affymetrix Human HG-U133
Plus 2.0 oligonucleotide microarray chips (Santa Clara, CA, USA),
covering over 47000 human transcripts and variants, were
performed following the manufacturer’s protocols.
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was
performed in triplicate by using primer sets and probes specific
for TFF3 gene (Assay on Demand Hs00173625_m1, Applied
Biosystems, Foster City, CA, USA). Complementary DNA synthesis
and PCR conditions were performed as previously described
(Bignotti et al, 2006).
Immunohistochemistry on formalin-fixed,
paraffin-embedded tissues
Immunostaining of 38 formalin-fixed, paraffin-embedded G3-EEC
and 22 NE tissues was performed as previously described (Bignotti
et al, 2006), using the TFF3 mouse monoclonal antibody 1mgml
 1
(Assay Designs, Ann Arbor, MI, USA). All samples were scored
quantitatively and qualitatively in 20 and 40 high-power fields in
every section (Nikon, Tokio, Japan, Eclipse E400). Slides were
blindly analysed by three independent pathologists, and the
scoring method was based on the intensity of the staining and
on the percentage of tumour cell stained. Intensity was scored as
follows: 0 indicating no staining; 1 weak staining; 2 moderate
staining; and 3 strong staining. The percentage of tumour cells
stained was scored as follows: 0 indicating no staining; 1 indicating
1–10%, 2 indicating 11–50%, and 3 indicating 51–100%. Then,
multiplying the intensity score against the percentage staining
score, we obtained a single scale with scores of 0, 1, 2, 3, 4, 6, and 9.
A total score was calculated grouping scores 1–3 in total score 1, 4,
and 6 in total score 2 and 9 in total score 3. Tissues with no
staining in term of intensity and percentage of positive cells (total
score¼0) were scored as negative.
TFF3 immunoassay
Serum TFF3 levels were measured by an in-house-specific ELISA,
and each sample was analysed in duplicate. We used human TFF3
full-length recombinant protein (Abnova Corporation, Taipei City,
Taiwan) for standard curve calibrator preparation, starting from a
stock solution of 114mgml
 1. The stock solution was diluted in assay
buffer (PBS 1% wt/vol bovine serum albumin, 0.05% Tween 20) to
obtain calibrators ranging from 1.25 to 0.019mgml
 1.W eu s e dt h e
assay buffer as zero calibrator. The mouse monoclonal antibody M01
clone 3D9 (Abnova Corporation) was used as capture antibody and
for detection the mouse monoclonal antibody MAB 4407 (R&D
Systems Inc., Minneapolis, MN, USA) previously biotinylated with a
biotin solution (AH-BIOTIN-NHS, Biospa, Milano, Italy), following
the manufacturer’s protocol. Coating of Maxisorp flat-bottomed
96-well microtiter plates (Dako, Glostrup, Denmark) was done
o v e r n i g h ta t4 1Ca d d i n g1 0 0 mlo f2 . 5 mgml
 1 anti-human TFF3
M01 clone 3D9 in carbonate/bicarbonate buffer (Na2CO3 0.0015 M,
NaHCO3 0.035 M) pH 9.6. Plates were subsequently washed four
times with PBS 0.05% Tween 20 and blocked with 200mlo f3 %
(wt/vol) BSA in PBS 0.05% Tween 20 for 2h at room temperature.
After one wash, 100ml of standard curve and human sera diluted 1:5
in assay buffer were incubated for 2h at room temperature.
After five washes, 100ml of biotinylated MAB 4407 antibody
(diluted 1:100 in assay buffer) was added, and the plates were
incubated for 2h at room temperature. After five washes, 100ml
of streptavidin peroxidase (Sigma-Aldrich Inc., St Louis, MO,
USA) diluted to a concentration of 1:2000 with PBS 1% BSA
was added to each well and incubated for 1h, followed by five
washes. The enzyme-catalyzed colour reaction was developed by
the addition of 100ml of tetramethylbenzidine liquid substrate
system (Sigma-Aldrich Inc.) to each well for 10min. The colour
development was stopped adding 100ml of 0.4 N sulphuric acid to
each well and plates were read at 450nm using an automatic plate
reader (Spectramax 340 PC, Molecular Devices Corporation,
Sunnyvale, CA, USA).
CA125 serum levels measurements
Serum CA125 values in all samples were determined by the clinical
laboratory at the Spedali Civili di Brescia, Italy, using the Architect
CA125 II chemiluminescent two-step immunoassay kit (Abbott
Diagnostics, Abbott Park, IL, USA) following the manufacturer’s
protocol.
Statistical data analysis and clustering
Gene expression values were first analysed with a nonspecific
filtering as previously reported (Bignotti et al, 2006). The
comparison between EEC and NE samples was performed using
the SAM algorithm (Tusher et al, 2001; Holger Schwender, 2007).
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sGenes were considered of interest if the absolute value of the
estimated fold change was equal or higher than 3, and if the fold
discovery rate was smaller than 5%. A hierarchical clustering using
1 Pearson’s correlation coefficient as distance matrix was
performed to graphically show the results of the analysis.
Spearman’s rank correlation was used to estimate the degree of
association between microarray and qRT-PCR data for TFF3 gene.
Exact Wilcoxon Mann–Whitney rank sum test was performed to
estimate the difference in TFF3 immunohistochemical expression
between EECs and NEs. Differences in TFF3 serum levels between
the groups were calculated using ANOVA on log-transformed
ELISA data. Spearman’s rank correlation was used to estimate
the degree of association between serum TFF3 and CA125
values. All the analyses were performed using the R (R
Development Core Team, 2008) and Bioconductor software
(Gentleman et al, 2004).
RESULTS
Gene expression analysis and clustering of EEC and NE
Comprehensive gene expression profiles of 19 snap-frozen G3-
EECs and 15 NEs were generated using high-density oligonucleo-
tide microarrays. The unsupervised hierarchical sample cluster
readily distinguished EECs from NEs showing two major branches.
As shown in Figure 1, all 19 EECs were found to group together in
the rightmost columns of the dendrogram, and similarly in the
leftmost columns, all 15 NEs were found to cluster tightly together.
After filtering out most ‘absent’ genes, the SAM analysis revealed a
total of 922 probe sets showing 43-fold change and a fold
discovery rate smaller than 5%. Out of 922 genes, 363 were found
upregulated in EECs when compared when NEs (see Supplemen-
tary data), and among them, several genes encoding membrane
and secreted proteins were found. Of great interest, owing to its
secreted nature, TFF3 was the top differentially expressed gene in
EECs, when compared with NE (fold change¼21). The second
profile was represented by 559 genes underexpressed in EECs and
overexpressed in NEs (see Supplementary data).
Validation of TFF3 gene expression by qRT-PCR
Quantitative real-time polymerase chain reaction technology was
used to validate the different TFF3 mRNA expression in EEC, when
compared with NE. Although data are not shown, we found qRT-
PCR data for TFF3 to be significantly correlated to the microarray
data (Po0.001; rs¼0.85). Thus, qRT-PCR data suggest that most
array probe sets are able to accurately measure the levels of the
intended transcript within a complex mixture of transcripts.
Validation of protein expression by immunohistochemical
staining
To confirm TFF3 gene expression results at the protein level,
immunohistochemistry for TFF3 was carried out on 38 G3-EECs and
22 NEs. As shown in Table 1 and representatively displayed in
Figure 2B, a positive cytoplasmatic staining for TFF3 was detected in
30 out of 38 (79%) EEC samples, whereas only 4 out of 22 (18%) NEs
showed a weak immunoreactivity for TFF3 (Table 1 and Figure 2A).
Tumour tissues showed markedly increased TFF3 positivity as
compared with normal tissues (Po0.01). Trefoil factor 3 staining in
EEC samples appeared to be diffuse, cytoplasmic, and restricted to
the epithelial compartment, with no positivity in adjacent stromal
cells. Trefoil factor 3 staining in tumour tissues appeared to be
moderate/strong (total score 2/3) in 40% of cases (Table 1).
TFF3 ELISA validation procedures
The assay sensitivity limit, defined as the concentration of TFF3
that can be distinguished from 0, was B5ngml
 1 of recombinant
TFF3 and detection was linear over a range of 20–1250ngml
 1
(r
2¼0.99). We tested recombinant TFF3 diluted in assay buffer or
‘spiked’ into normal sera (at the same concentrations used for the
standard curve), comparing the results using the ELISA assay.
Recoveries were then calculated after subtraction of the serum










































































































































Figure 1 Dendrogram resulting from unsupervised cluster analysis
differentiating EECs from NEs by gene expression profiling. The cluster is
colour coded using red for upregulation, green for downregulation, and
black for median expression.












TFF3 staining (total score)
a
0 8 (21%) 18 (82%)
1 15 (39%) 4 (18%)
2 8 (21%) 0
3 7 (19%) 0
EEC¼endometrioid endometrial carcinomas; NE¼normal endometrial cells;
TFF3¼trefoil factor 3.
aTFF3 staining indicates scoring method was based on the
intensity of the staining and on the percentage of tumour cells stained as described in
the Materials and Methods section.
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sfrom 88 to 100% in serum, when compared with assay buffer (data
not shown). To evaluate the method reliability, four serum samples
with different TFF3 levels, ranging from 500 to 1500ngml
 1,w e r e
analysed eight times in the same ELISA experiment and on 6 different
days. The intra-assay and inter-assay coefficients of variation (CV)
were between 1.6–4.2 and between 4.1–8.2%, respectively.
Serum TFF3 levels
Table 2 shows the average TFF3 serum concentrations for patients
with G3 endometrial cancer with endometrial hyperplasia and for
healthy controls. Trefoil factor 3 serum concentration was
significantly higher in patient with EEC compared with NE
(Po0.001) and in EEC compared with EH (P¼0.012). No
difference was observed between serum TFF3 levels in EH, when
compared with NE. Figure 3 displays TFF3 distribution for the
three groups of patients. In this regard, to obtain a graphical plot
of the sensitivity vs specificity of TFF3 levels for detecting and to
better discriminate G3-EEC from controls, ROC curves were used.
Using a cutoff value of 752ngml
 1, the sensitivity and specificity
of serum TFF3 for discriminating EEC from NE were 56 and
85%, respectively (Table 3), whereas setting a cutoff value of
587ngml
 1, the sensitivity and specificity of serum TFF3 for
detecting EEC compared with EH were 71 and 77%, respectively.
Comparison of TFF3 and CA125 levels
We analysed CA125 serum levels in 25 G3-EEC patients and
42 controls tested with TFF3 ELISA. When the cutoff value was set
at 35Uml
 1, the sensitivity of CA125 was 16% (4 of 25), whereas
the specificity was 93% (39 of 42, Table 3). The sensitivity of CA125
in the detection of early-stage EECs was further decreased with
only 10% of the stage I patients having a CA125435Uml
 1. In the
same group of patients, TFF3 assay was able to detect 60% (6 out of
10) of EEC at stage I. When the CA125 cutoff level was decreased at
20Uml
 1, as shown in Table 3, its sensitivity when compared with
TFF3 remained significantly lower (i.e., 32 vs 56%, respectively).
Because CA125 and TFF3 levels were not significantly correlated
either in tumour patients or in negative controls, a combination of
the two markers was analysed. The sensitivity and specificity of
each marker and of the combination of the two are shown in
Table 3. The combination of CA125 and TFF3 led to a sensitivity of
60% and a specificity of 67% considering all EEC stages.
Table 2 TFF3 and CA125 quantification in patient sera
CA125 (Uml
 1) TFF3 (ngml
 1)
Patient group n Range Mean Range Mean
EEC 25 4–853 46 213–2890 955
EH 13 9–61 20 409–813 523
NE 47 1–96 16 226–1101 556
EEC¼endometrioid endometrial carcinomas; EH¼endometrial hyperplasia cells;


























Figure 3 Trefoil factor 3 ELISA scatter plot in serum of poorly
differentiated endometrioid endometrial cancer (EEC), endometrial
hyperplasia (EH), and normal endometria (NE) patients. The cutoff value
of 752ngml
 1 is reported.


















a 32 16 56 60
Specificity




number of truepositives þ number of falsenegatives
bspecificity ¼
number of truenegatives
number of truenegatives þ number of falsepositives
AB
Figure 2 Representative immunohistochemical staining for TFF3. (A) Normal secretory endometrium showing no cytoplasmatic staining for TFF3 (total
score¼0, original magnification  20). (B) Poorly differentiated endometrioid endometrial cancer displaying a strong cytoplasmatic positivity for TFF3 (total
score¼3, original magnification  20). Trefoil factor 3 staining in EEC samples appeared to be diffuse, cytoplasmic, and restricted to the epithelial
compartment, with no positivity in adjacent stromal cells. Arrows shows TFF3-positive epithelial cells vs the non-expressing stromal cells. Scale bar¼50mm.
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Endometrial cancer is the most common gynaecologic malignancy
in developed countries and it is generally considered a
neoplasia with good prognosis. Indeed, most of the patients, due
to the early declaration of the disease by vaginal bleeding, are
diagnosed at an early stage and with Type I EC. Nevertheless, up to
35% of EC patients may be diagnosed with biologically aggressive
Type II tumours, with G3-EEC accounting for the majority
of the cases (Bokhman, 1983). For several of these patients, the
prognosis remains poor, regardless of their treatment with gold
standard therapies including surgery, adjuvant radiation, and/or
chemotherapy. Furthermore, few EC markers are currently
available to monitor the effects of adjuvant therapy or to
predict early tumour recurrence. In this regard, although
CA125 is commonly used in the clinic for these purposes, it is
endowed with low sensitivity and specificity (Sood et al, 1997;
Powell et al, 2005).
In the present investigation, with the aim to discover new
diagnostic molecular markers for G3-ECC, we have analysed the
gene expression profile of G3-EECs, the most common Type II
uterine cancer. A genome wide examination of this aggressive
tumour variant with the more comprehensive Affymetrix chip
currently available (i.e., HG-U133 plus 2.0 covering 47000 human
transcripts and variants) has provided evidence that G3-ECC
genetic fingerprints can be clearly distinguished from those
of NE. Indeed, we detected 922 differentially expressed genes,
whose average change in expression level between the two
groups was at least threefold. At the top of overexpressed genes
in EECs compared with NEs, with a fold change of 21, TFF3 was
found.
Trefoil factor 3 belongs to a family of small, compact peptides
containing one or two trefoil domains, consisting of 42 to 43 amino
acids with six cysteine residues forming three disulphide bonds,
giving the characteristic three-leafed structure (Thim, 1997).
Trefoil factor 3 was recognised for the first time in rat intestine,
and it has been shown to be primarily expressed and secreted onto
the intestinal surface by goblet cells of the human small and large
intestinal mucosa (Suemori et al, 1991; Podolsky et al, 1993). The
main reported TFF3 role in the gastrointestinal tract involves the
reconstitution of the mucosal barrier to protect the epithelial layer
against environmental injury induced by ulceration and inflam-
mation, increasing the rate of epithelial migration into the wound
(Dignass et al, 1994; Xian et al, 1999).
Trefoil factor 3 has been shown to be expressed in several
normal tissues including hypothalamus/pituitary, breast, conjunc-
tiva, and salivary gland (Probst et al, 1996; Poulsom et al, 1997;
Langer et al, 1999; Devine et al, 2000). Abnormally elevated
levels of TFF3 have been documented in breast, pancreatic, gastric,
and prostate carcinomas (Theisinger et al, 1996; Terris et al, 2002;
Yamachika et al, 2002; Garraway et al, 2004). Importantly,
overexpression of TFF3 has been reported to be prognostically
important in several of these cancers (Yamachika et al, 2002;
Yio et al, 2004). Nevertheless, little is known about whether TFF3
directly contributes to the malignant behaviour of cancer cells.
In this regard, TFF3 has been shown to regulate cancer progression
by increasing tumour metastasis acting as anti-apoptotic, scatter-
ing, pro-invasive, and angiogenic agent on cancer cells
(Taupin et al, 2000; Emami et al, 2001; Rodrigues et al, 2003).
Trefoil factor 3 expression in the human uterus has been analysed
by several investigators with conflicting results. For instance,
Wiede et al (2001) reported low TFF3 mRNA levels by qRT-PCR
and no detectable TFF3 protein expression in the NE by
Western blot analysis. Accordingly, Madsen et al (2007) found
few endometrial cells positively stained for TFF3 by immuno-
histochemistry. In contrast, Borthwick et al (2003) documented
different TFF3 transcript levels during the phases of the
menstrual cycle, with a major TFF3 expression in proliferative
compared with secretory endometrium, suggesting its
role in regeneration of the human endometrium following
menstruation.
According to our microarray results, TFF3 mRNA was found
to be consistently upregulated in the majority of G3-EEC speci-
mens as compared with NE tissues. Gene expression results have
been validated successfully on the same set of samples by qRT-
PCR, confirming TFF3 gene expression profiling data. Moreover,
we demonstrated TFF3 overexpression in G3-EEC tissues by
immunohistochemical staining, providing the first evidence of
TFF3 protein upregulation in EC. In agreement with previous
reports, TFF3 was found negative or focally positive by immu-
nostaining in NE (Wiede et al, 2001; Madsen et al, 2007). In
contrast to the result of Borthwick et al, however, we did not
observe significant differences in TFF3 mRNA or protein
expression between the different menstrual cycle phases in NE
(data not shown).
Importantly, as TFF3 is a secreted peptide, it may represent a
novel, potentially useful diagnostic biomarker in G3-EEC
patients. Consistent with this view, TFF3 levels were measured
by a specific in-house ELISA developed in our laboratory in 25
G3-EEC patients treated at our Institution. Our results showed a
significantly higher TFF3 serum level in EEC patients
when compared with healthy women or patients harbouring
endometrial hyperplasia. More importantly, TFF3 serum levels
showed higher sensitivity in the detection of patients harbouring
G3-EEC when compared with CA125 (cutoff¼35Uml
 1). Further-
more, similar results were found when CA125 was compared with
TFF3 levels at a cutoff value of 20Uml
 1, reported by several
investigators to be more appropriate for preoperative evaluation
and post-operative surveillance of EC patients (Sood et al, 1997;
Kurihara et al, 1998). Indeed, even at this lower CA125 setting,
TFF3 remained a more sensitive indicator of tumour presence than
CA125. Finally, when we analysed the combined ability of CA125
and TFF3 serum markers in detecting endometrial cancer,
we found no significant improvement when compared with
TFF3 alone.
In conclusion, several novel tumour-restricted markers
have been identified through our genome-wide analysis of
G3-EEC. The identification of TFF3 as a novel diagnostic
biomarker endowed with a sensitivity and specificity superior to
that of CA125 in the preoperative evaluation of G3-EEC patients, as
demonstrated in this pilot work, may support the design of
prospective studies evaluating the potential of TFF3 as a new tool
for preoperative evaluation and post-operative surveillance of EC
patients.
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